Results 101 to 110 of about 319 (119)

Old and new strategies in therapy and diagnosis against fungal infections. [PDF]

Appl Microbiol Biotechnol
Vanzolini T, Magnani M.
europepmc   +1 more source

cyp51A Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the Aspergillus viridinutans Species Complex. [PDF]

Antimicrob Agents Chemother, 2019
Talbot JJ, Frisvad JC, Meis JF, Hagen F, Verweij PE, Hibbs DE, Lai F, Groundwater PW, Samson RA, Kidd SE, Barrs VR, Houbraken J.   +11 more
europepmc   +1 more source

Olorofim activity against multidrug-resistant Fusarium unveils intra-species and inter-species variability. [PDF]

Antimicrob Agents Chemother
Xue R, Gao S, de Hoog S, van Diepeningen A, Zhou S, Xu T, Fokkens L, Li R, Bai L, Wan Z, Verweij PE, Song Y.   +11 more
europepmc   +1 more source

In vitro Models to Describe the Pharmacokinetics and Pharmacodynamics of New and Existing Antifungal Agents [PDF]

Box, HJ
core  

New antifungal strategies and drug development against WHO critical priority fungal pathogens. [PDF]

Front Cell Infect Microbiol
Li Y, Liu Y, Jiang Y, Yang Y, Ni W, Zhang W, Tan L.   +6 more
europepmc   +1 more source

Errata. [PDF]

J Infect Dis, 2018
europepmc   +1 more source

Meeting the Therapeutic Challenges of Emergent and Rare Invasive Fungal Diseases Through Novel Clinical Trial Designs. [PDF]

Open Forum Infect Dis
Walsh TJ.
europepmc   +1 more source

Advancements and challenges in antifungal therapeutic development. [PDF]

Clin Microbiol Rev
Puumala E, Fallah S, Robbins N, Cowen LE.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus

International Journal of Antimicrobial Agents, 2020
In recent decades, invasive infections caused by fungal pathogens have been reported with increasing frequency. Concurrently, the rates of detected resistance mechanisms against commonly used antifungal agents in fungi are increasing. The need for novel antifungal drugs is thus imminent.
Lisa Kirchhoff, Jan J Buer, Joerg Steinmann   +2 more
exaly   +3 more sources

Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical isolates, and review of azole resistance phenotype and genotype epidemiology in China.

2021
Triazole resistance in A. fumigatus is an increasing worldwide problem that causes major challenges in the management of aspergillosis. New antifungal drugs are needed with novel targets, that are effective in triazole-resistant infection. In this study, we retrospectively evaluated potency of the novel drug olorofim compared to contemporary antifungal
Su, Huilin, Zhu, Min, Tsui, Clement Kin-Ming, van der Lee, Henrich, Tehupeiory-Kooreman, Marlou, Zoll, Jan, Engel, Tobias, Li, Li, Zhu, Junhao, Lu, Zihan, Zhang, Qiangqiang, Verweij, Paul E, Deng, Shuwen   +12 more
openaire   +1 more source